poisar

Stocks · News reference

10x Genomics Announces Xenium Platform Deployment for Breast Cancer Biomarker Study

Fiscal.ai

10x Genomics, Inc. announced that Fudan University Shanghai Cancer Center and Shanghai Precision Diagnostics Co. Ltd will utilize its Xenium platform in a 24-month study to identify biomarkers for breast cancer neoadjuvant therapy response.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading